Paul Manning
Paul Manning is a prominent investor in AveXis, the biotech company responsible for developing Zolgensma, the world’s most expensive drug. His significant financial backing and involvement in the startup have raised questions about the motivations behind high drug prices and the commercialization of gene therapies.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| United Kingdom | 4 | 6.25 | 0.14% | +10% | 67,886,011 | 106,869 | $2,700,000 | 4,250$ |
| Totals | 4 | 67,886,011 | 106,869 | $2,700,000 | 4,250$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United Kingdom:
Paul Manning is the chief executive officer at Sensient.
5
United Kingdom:
Paul Manning, CEO at Sensient, explains the process of creating natural colors from raw materials.
6
United Kingdom:
Paul Manning is the chief executive officer at Sensient, which creates natural colours for food.
7
United Kingdom:
Paul Manning is the chief executive officer at Sensient, creating natural colors from raw materials.
7
United States:
Paul Manning, the company’s chief executive at Sensient Technologies Corp., discussed the supply issues related to natural dyes.
5
New Zealand:
Liquidator Paul Manning told the Bay of Plenty Times the investigation into a potential claim against a previous funder related to a government funder.
6
United States:
Paul Manning was a major investor in AveXis and made significant profits from the company's acquisition by Novartis.
5